Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00566696 · OUTCOME

To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies · Source last updated 2020-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
five years post-transplant

What was measured

The Cumulative Incidence of Relapse will be reported as the proportion of number of relapses since transplant to the total number of patients at risk at five years post-transplant.

Groups in this outcome

High-Risk Hematologic Malignancies

Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
High-Risk Hematologic Malignancies31

Reported measurements

The Cumulative Incidence of Relapse at five year p
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
High-Risk Hematologic Malignancies30.0Not reportedNot reportedNot reportedNot reported
Estimate±SE
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
High-Risk Hematologic Malignancies8.6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        30.0
    title
    The Cumulative Incidence of Relapse at five year p
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        8.6
    title
    Estimate±SE
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
The Cumulative Incidence of Relapse will be reported as the proportion of number of relapses since transplant to the total number of patients at risk at five years post-transplant.
groups
  1. description
    Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.
    id
    OG000
    title
    High-Risk Hematologic Malignancies
param Type
NUMBER
reporting Status
POSTED
time Frame
five years post-transplant
title
To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice